Causal Models Drive Preference between Drugs that Treat a Focal versus Multiple Symptoms

Kelly Saporta-Sorozon, Shai Danziger, Steven Sloman

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

This research examines the effects of causal beliefs on drug preference. In three studies, 374 undergraduate participants imagined that they suffered from a focal symptom and then indicated their preference between a drug claiming to treat only the focal symptom (single treatment) and a drug claiming to treat the focal symptom and a nonfocal symptom (dual treatment) they thought resulted from a common-cause or from a different cause. Participants who thought that the symptoms resulted from different causes significantly preferred the single treatment drug more and the dual treatment drug less than participants who thought the symptoms resulted from a common-cause. Process analysis yielded a significant mediation effect. Specifically, an individual's causal model determines preference by affecting the estimates of the potential gain and loss associated with using each drug. Participants who held a common-cause model concerning the source of the symptoms thought they would be more likely to need the nonfocal treatment provided by the dual treatment drug and less likely to suffer from side effects when taking this drug, than those with a different-cause model. The results demonstrate the influence of causal structure on judgment and choice.

Original languageEnglish
Pages (from-to)794-806
Number of pages13
JournalJournal of Behavioral Decision Making
Volume30
Issue number4
DOIs
StatePublished - 1 Oct 2017
Externally publishedYes

Keywords

  • causal model theory
  • causal structure
  • consumer reasoning
  • judgment
  • preference

ASJC Scopus subject areas

  • General Decision Sciences
  • Arts and Humanities (miscellaneous)
  • Applied Psychology
  • Sociology and Political Science
  • Strategy and Management

Fingerprint

Dive into the research topics of 'Causal Models Drive Preference between Drugs that Treat a Focal versus Multiple Symptoms'. Together they form a unique fingerprint.

Cite this